Leishmania/HIV co-infections in the second decade

Indian Journal of Medical Research

Volumn 123, Issue 3, 2006, Pages 357-388

  Cruz, Israel ^a   Nieto, Javier ^a   Moreno, Javier ^b   Cañavate, Carmen ^a   Desjeux, Philippe ^c,e   Alvar, Jorge ^d  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^c Institute for OneWorld Health   (United States)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e Institute for Oneworld Health (iOWH)   (France)

Author keywords

Co infection; HIV; Immunotherapy; Leishmania; Pathogenesis

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; ANTIMONY DERIVATIVE; ANTIRETROVIRUS AGENT; GAMMA INTERFERON; KETOCONAZOLE; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; PENTOSTAN; RECOMBINANT COLONY STIMULATING FACTOR 1; STIBOGLUCONATE SODIUM; TUCARESOL;

ACUTE KIDNEY FAILURE; AGGLUTINATION TEST; ANOREXIA; ARTHRALGIA; BRAZIL; CLINICAL PROTOCOL; CLINICAL TRIAL; DIABETES MELLITUS; DIAGNOSTIC TEST; DISEASE TRANSMISSION; DRUG DELIVERY SYSTEM; DRUG FEVER; DRUG HALF LIFE; ENZYME IMMUNOASSAY; ETHIOPIA; GASTROINTESTINAL DISEASE; GRANULOCYTOPENIA; HEADACHE; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPOTENSION; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOTHERAPY; INDIA; INJECTION SITE PAIN; KIDNEY FAILURE; LEISHMANIA; LEISHMANIASIS; LYMPHOCYTE PROLIFERATION; MICROSCOPY; MOLECULAR BIOLOGY; MYALGIA; MYOCARDITIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; PANCREATITIS; PATHOGENESIS; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY TRACT DISEASE; REVIEW; SECONDARY PREVENTION; SEROLOGY; SKIN DISEASE; SOUTHERN EUROPE; SUDAN; SUPERINFECTION; SYMPTOM; TACHYCARDIA; TASTE DISORDER; TREATMENT OUTCOME; TREMOR; VOMITING;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE TRANSMISSION; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY; LEISHMANIA; LEISHMANIASIS;

EID: 33745182866     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (303)

1. De la Loma A, Alvar J, Martínez-Galiano E, Blázquez J, Alcalá-Muñoz A, Nájera R. Leishmaniasis or AIDS? Trans R Soc Trop Med Hyg 1985; 79: 421-2.
2. Desjeux P, Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol 2003; 97: S3-15.
3. WHO. Report on the consultative meeting on Leishmanial HIV co-infection. WHO/LEISH/95.35. Geneva: World Health Organization; 1995 p. 1-4.
4. Leishmania/HIV co-infection. Epidemiological analysis of 692 retrospective cases. Wkly Epidemiol Rec 1997; 72: 49-54.
5. Leishmania/HIV co-infection, south western Europe, 1990-1998. Wkly Epidemiol Rec 1999; 74: 365-75.
6. Pintado V, Martín-Rabadán P, Rivera ML, Moreno S, Bouza E. Visceral leishmaniasis in human-immunodeficiency virus (HIV)-infected and non HIV-infected patients. Medicine 2001; 80: 54-73.
7. Kubar J, Marty P, Lelievre A, Quaranta JF, Staccini P, Caroli-Bosc C, et al. Visceral leishmaniosis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocyte counts. AIDS 1998; 12: 2147-53.
8. Alvar J, Gutiérrez-Solar B, Molina R, López-Vélez R, García-Camacho A, Martínez P, et al. Prevalence of Leishmania infection among AIDS patients. Lancet 1992; 339: 264-5.
9. Sampaio RN, Salaro CP, Resende P, De Paula CD. American cutaneous leishmaniasis associated with HIV/AIDS: report of four clinical cases. Rev Soc Bras Med Trop 2002; 35: 651-4.
10. Rabello A, Orsini M, Disch J. Leishmania/HIV co-infection in Brazil: an appraisal. Ann Trop Med Parasitol 2003; 97: S17-28.
11. Guiguemde RT, Sawadogo OS, Bories C, Traore KL, Nezien D, Nikiema L, et al. Leishmania major and HIV co-infection in Burkina Faso. Trans R Soc Trop Med Hyg 2003; 97: 168-9.
12. Mukhtar MM, Khalil AM, Elhassan AM, Musa F, Modabber F. Leishmania first generation vaccines: vaccine trials in Sudan. In: Mas-Coma S, Bargues MD, Esteban JG, Valero MA, editors. IX European Multicolloquium of Parasitology, Valencia, Spain 2004; KS : 128.
13. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 2001; 6: 849-54.
14. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347: 1739-46.
15. Sinha PK, Rabidas VN, Pandey K, Verma N, Gupta AK, Ranjan A, et al. Visceral leishmaniasis and HIV coinfection in Bihar, India. J Acquir Immune Defic Syndr 2003; 32: 115-6.
16. Albrecht HI, Sobottka I, Emminger C, Jablonowski H, Just G, Stoehr A, et al. Visceral leishmaniasis emerging as an important opportunistic infection in HIV-infected persons living in areas nonendemic for Leishmania donovani. Arch Pathol Lab Med 1996; 120: 189-98.
17. Rosenthal E, Marty P, Poizot-Martin I, Reynes J, Pratlong F, Lafeuillade A, et al. Visceral leishmaniasis and HIV-1 co-infection in southern France. Trans R Soc Trop Med Hyg 1995; 89: 159-62.
18. Gradoni L, Scalone A, Gramiccia M, Troiani M. Epidemiological surveillance of leishmaniasis in HIV-1-infected individuals in Italy. AIDS 1996; 10: 785-91.
19. López-Vélez R, Pérez-Molina JA, Guerrero A, Baquero F, Villarrubia J, Escribano L, et al. Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. Am J Trop Med Hyg 1998; 58: 436-43.
20. Botet J, Portús M. La leishmaniosis en la España peninsular. Revision histórico-bibliográfica (1912-1985). Rev San Hig Pub 1993; 67: 255-66.
21. Alvar J. Leishmaniasis and AIDS co-infection: the Spanish example. Parasitol Today 1994; 10: 160-3.
22. Montalbán C, Calleja JL, Erice A, Laguna F, Clotet B, Podzamczer D, et al. Visceral leishmaniasis in patients infected with human immunodeficiency virus. Co-operative Group for the Study of Leishmaniasis in AIDS. J Infect 1990; 21: 161-70.
23. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
24. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352: 1725-30.
25. Del Giudice P, Mary-Krause M, Pradier C, Grabar S, Dellamonica P, Marty P, et al. French Hospital Database on HIV Clinical Epidemiologic Group. Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus. J Infect Dis 2002; 186: 1366-70.
26. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277: 112-6.
27. Tural C, Romeu J, Sirera G, Andreu D, Conejero M, Ruiz S, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis 1998; 177: 1080-3.
28. Weverling GJ, Mocroft A, Ledergerber B, Kirk O, González-Lahoz J, D'Arminio-Monforte A, et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet 1999; 353: 1293-8.
29. Jouan M, Saves M, Tubiana R, Carcelain G, Cassoux N, Aubron-Olivier C, et al. RESTIMOP study team. Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2001; 15: 23-31.
30. López Bernaldo de Quirós JC, Miró JM, Pena JM, Podzamczer D, Alberdi JC, Martínez E, et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. N Engl J Med 2001; 344: 159-67.
31. Carr A, Marrito D, Field A, Vasak E, Cooper DA. Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet 1998; 351: 256-61.
32. Foudraine NA, Weverling GJ, Van Gool T, Roos MT, De Wolf F, Koopmans PP, et al. Improvement of chronic diarrhoea in patients with advanced HIV-1 infection during potent antiretroviral therapy. AIDS 1998; 12: 35-41.
33. Miró JM, López JC, Podzamczer D, Peña JM, Alberdi C, Claramonte X, et al. GESIDA 04/98-B Study. Discontinuation of toxoplasmic encephalitis prophylaxis is safe in HIV-1 and T. gondii coinfected patients after immunological recovery with HAART: Preliminary results of the GESIDA 04/98-B study. San Francisco: Proceedings of the 7th Conference on Retroviruses and Opportunistic Infections (Abstract Book); 2000.
34. López-Vélez R. The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV. Ann Trop Med Parasitol 2003; 97: S143-7.
35. Russo R, Nigro L, Panarello G, Montineri A. Clinical survey of Leishmania/HIV co-infection in Catania, Italy: the impact of highly active antiretroviral therapy (HAART). Ann Trop Med Parasitol 2003; 97: S149-55.
36. De la Rosa R, Pineda JA, Delgado J, Macías J, Morillas F, Mira JA, et al. Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy. J Clin Microbiol 2002; 40: 762-7.
37. López-Vélez R, Casado JL, Pintado V. Decline of a visceral leishmaniasis epidemic in HIV-infected patients after the introduction of highly active antiretroviral therapy (HAART). Clin Microbiol Infect 2001; 7: 394-5.
38. Mira JA, Corzo JE, Rivero A, Macías J, De León FL, Torre-Cisneros J, et al. Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. Am J Trop Med Hyg 2004; 70: 298-301.
39. UNAIDS. AIDS Epidemic Update 2002. www.unaids.org, accessed on April 8, 2005.
40. Fisk DT, Meshnick S, Kazanjian PH. Pneumocystis carinii pneumonia in patients in the developing world who have acquired immunodeficiency syndrome. Clin Infect Dis 2003; 36: 70-8.
41. Desjeux P. Leishmania and HIV co-infection in southwestern Europe, 1990-1998, retrospective analysis of 965 cases. Geneva: World Health Organization, WHO/Leish/2000.42 2000.
42. WHO. The world health report. Geneva: World Health Organization 2001.
43. Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2002; 2: 494-501.
44. Molina R, Gradoni L, Alvar J. HIV and the transmission of Leishmania. Ann Trop Med Parasitol 2003; 97: S29-S45.
45. Desjeux P, UNAIDS. Leishmania and HIV in Gridlock. WHO/CTD/LEISH/98.9 Add.I, UNAIDS/98.23.1998. Geneva: World Health Organization; 1998.
46. Alvar J, Cañavate C, Gutiérrez-Solar B, Jiménez MI, Laguna F, López-Vélez R, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997; 10: 298-319.
47. Pratlong F, Dereure J, Deniau M, Marty P, Faraut-Gambarelli F, Dedet JP. Enzymatic polymorphism during Leishmania/HIV co-infection: a study of 381 Leishmania strains received between 1986 and 2000 at the international cryobank in Montpellier, France. Ann Trop Med Parasitol 2003; 97: S47-56.
48. Molina R, Cañavate C, Cercenado E, Laguna F, López-Vélez R, Alvar J. Indirect xenodiagnosis of visceral leishmaniasis in 10 HIV-infected patients using colonized Phlebotomus perniciosus. AIDS 1994; 8: 277-9.
49. Cruz I, Morales MA, Noguer I, Rodríguez A, Alvar J. Leishmania in discarded syringes from intravenous drug users. Lancet 2002; 359: 1124-5.
50. Pineda JA, Macías J, Morillas F, Fernández-Ochoa J, Cara J, De La Rosa R, et al. Evidence of increased risk for Leishmania infantum infection among HIV-seronegative intravenous drug users from southern Spain. Eur J Clin Microbiol Infect Dis 2001; 20: 354-7.
51. Pineda JA, Martín-Sánchez J, Macías J, Morillas F. Leishmania spp infection in injecting drug users. Lancet 2002; 360: 950-1.
52. Rosenthal PJ, Chaisson RE, Hadley WK, Leech JH. Rectal leishmaniasis in a patient with acquired immunodeficiency syndrome. Am J Med 1988; 84: 307-9.
53. Heisch R. Studies in leishmaniasis in East Africa. I. The epidemiology of an outbreak of kala-azar in Kenya. Trans R Soc Trop Med Hyg 1954; 48: 449-69.
54. Aggarwal P, Wali JP. Profile of kala-azar in north India. Asia-Pacific J Public Health 1991; 5: 90-3.
55. Evans TG, Teixeira MJ, McAuliffe IT, Vasconcelos I, Vasconcelos AW, Sousa A de A, et al. Epidemiology of visceral leishmaniasis in northeast Brazil. J Infect Dis 1992; 166: 1124-32.
56. Belazzoug S. Leishmaniasis in Mediterranean countries. Vet Pathol 1992; 44: 15-9.
57. Cascio A, Colomba C, Antinori S, Orobello M, Paterson D, Titone L. Pediatric visceral leishmaniasis in Western Sicily, Italy: a retrospective analysis of 111 cases. Eur J Clin Microbiol Infect Dis 2002; 21: 277-82.
58. Kafetzis DA. An overview of paediatric leishmaniasis. J Postgrad Med 2003; 49: 31-8.
59. Berenguer J, Moreno S, Cercenado E, Bernaldo de Quirós JC, García de la Fuente A, Bouza E. Visceral leishmaniasis in patients infected with human immunodeficiency virus (HIV). Ann Intern Med 1989; 111: 129-2.
60. Pineda JA, Gallardo JA, Macías J, Delgado J, Regordan C, Morillas F, et al. Prevalence of and factors associated with visceral leishmaniasis in human immunodeficiency virus type 1-infected patients in southern Spain. J Clin Microbiol 1998; 36: 2419-22.
61. Alexander J. Sex differences and cross-immunity in DBA/2 mice infected with L. mexicana and L. major. Parasitology 1988; 96: 297-302.
62. Brabin L, Brabin BJ. Parasitic infections in women and their consequences. Adv Parasitol 1992; 31: 1-81.
63. Ahluwalia IB, Bern C, Wagatsuma Y, Costa C, Chowdhury R, Ali M, et al. Visceral leishmaniasis: consequences to women in a Bangladeshi community. J Womens Health (Larchmt) 2004; 13: 360-4.
64. Medrano FJ, Hernández-Quero J, Jiménez E, Pineda JA, Rivero A, Sánchez-Quijano A, et al. Visceral leishmaniasis in HIV-1-infected individuals: a common opportunistic infection in Spain? AIDS 1992; 6: 1499-503.
65. Ribera E, Cucurull E, Ocaña I, Vallespi T, Gasser I, Juste C. Visceral leishmaniasis in patients with HIV infection. Enferm Infecc Microbiol Clin 1995; 13: 73-9.
66. Russo R, Laguna F, López-Vélez R, Medrano FJ, Rosenthal E, Cacopardo B, et al. Visceral leishmaniasis in those infected with HIV: clinical aspects and other opportunistic infections. Ann Trop Med Parasitol 2003; 97: S99-105.
67. Berhe N, Wolday D, Hailu A, Abraham Y, Ali A, Gebre-Michael T, et al. HIV viral load and response to antileishmanial chemotherapy in co-infected patients. AIDS 1999; 13: 1921-5.
68. Pintado V, López-Vélez R. Visceral leishmaniasis associated with human immunodeficiency virus infection. Enferm Infecc Microbiol Clin 2001; 19: 353-7.
69. Da-Cruz AM, Machado ES, Menezes JA, Rutowitsch MS, Coutinho SG. Cellular and humoral immune responses of a patient with American cutaneous leishmaniasis and AIDS. Trans R Soc Trop Med Hyg 1992; 86: 511-2.
70. Machado ES, Braga MP, Da-Cruz AM, Coutinho SG, Vieira ARM, Rutowitsch MS, et al. Disseminated merican muco-cutaneous leishmaniasis caused by Leishmania braziliensis braziliensis in a patient with AIDS: a case report. Mem Inst Oswaldo Cruz 1992; 87: 487-92.
71. Echevarría J, Campos P, Chang J, Cuéllar L, Gotuzzo E, Paz L, et al. Mucocutaneous leishmaniasis and AIDS. Trans R Soc Trop Med Hyg 1993; 87: 186.
72. Hernández DE, Oliver M, Martínez C, Planas G. Visceral leishmaniasis with cutaneous and rectal dissemination due to Leishmania braziliensis in acquired immunodeficiency syndrome (AIDS). Int J Dermatol 1995; 34: 114-5.
73. Romero HD, Taranto NJ, Malchiodi EL. American tegumentary leishmaniasis associated with AIDS in Argentina. Medicina (B Aires) 2004; 64: 47-50.
74. Berhe N, Hailu A, Gemetchu T. Human immunodeficiency virus and recurrence of cutaneous leishmaniasis long after healed localized cutaneous leishmaniasis due to Leishmania aethiopica. Trans R Soc Trop Med Hyg 1995; 89: 400-1.
75. CDC (Centers for Disease Control). Viscerotropic leishmaniasis in persons returning from operation Desert Storm 1990-1991. Morbid Mortal Wkly Rep 1992; 41: 131-4.
76. Magill AJ, Grogl M, Fasser RA, Wellington S, Oster CN. Viscerotropic leishmaniasis caused by Leishmania tropica in soldiers returning from Operation Desert Storm. N Engl J Med 1993; 328: 1383-7.
77. Gillis D, Klaus S, Schnur LF, Piscopos P, Maayan S, Okon E, et al. Diffusely disseminated cutaneous Leishmania major infection in a child with acquired immunodeficiency syndrome. Pediatr Infect Dis 1995; 514: 247-9.
78. Jiménez M, Ferrer-Dufol M, Cañavate C, Gutiérrez-Solar B, Molina R, Laguna F, et al. Variability of Leishmania (Leishmania) infantum among stocks from immunocompromised, immunocompetent patients and dogs in Spain. FEMS Microbiol Lett 1995; 131: 197-204.
79. Chicharro C, Jiménez MI, Alvar J. Iso-enzymatic variability of Leishmania infantum in Spain. Ann Trop Med Parasitol 2003; 97: S57-64.
80. Barral A, Badaró R, Barral-Netto M, Grimaldi G Jr, Momem H, Carvalho EM. Isolation of Leishmania mexicana amazonensis from the bone marrow in a case of American visceral leishmaniasis. Am J Trop Med Hyg 1986; 35: 732-4.
81. Barral A, Pedral-Sampaio D, Grimaldi G Jr, Momen H, McMahon-Pratt D, Ribeiro de Jesús A, et al. Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease. Am J Trop Med Hyg 1991; 44: 536-46.
82. Ramos-Santos C, Hernández-Montes O, Sánchez-Tejeda G, Monroy-Ostria A. Visceral leishmniosis caused by Leishmania (L.) mexicana in a mexican patient with human immunodeficiency virus infection. Mem Inst Oswaldo Cruz 2000; 95: 733-7.
83. Silva ES, Pacheco RS, Gontijo CM, Carvalho IR, Brazil RP. Visceral leishmaniasis caused by Leishmania (Viannia) braziliensis in a patient infected with human immunodeficiency virus. Rev Inst Med Trop Sao Paulo 2002; 44: 145-9.
84. Bosch RJ, Rodrigo AB, Sánchez P, de Gálvez MV. Presence of Leishmania organisms in specific and non-specific skin lesions in HIV-infected individuals with visceral leishmaniasis. Int J Dermatol 2002; 41: 670-5.
85. Ponce C, Ponce E, Morrison A, Cruz A, Kreutzer R, McMahon-Pratt D, et al. Leishmania donovani chagasi: new clinical variant of cutaneous leishmaniasis in Honduras. Lancet 1991; 337: 67-70.
86. Orsini M, Silva M, Luz ZM, Disch J, Fernandes O, Moreira D, et al. Identification of Leishmania chagasi from skin in Leishmania/HIV co-infection: a case report. Rev Soc Bras Med Trop 2002; 35: 259-62.
87. González-Beato MJ, Moyano B, Sánchez C, González-Beato MT, Pérez-Molina JA, Miralles P, et al. Kaposi's sarcoma-like lesions and other nodules as cutaneous involvement in AIDS-related visceral leishmaniasis. Br J Dermatol 2000; 143: 1316-8.
88. Mosier D, Sieburg H. Macrophage-tropic HIV: critical for AIDS pathogenesis? Immunol Today 1994; 15: 332-9.
89. Olivier M, Badaró R, Medrano FJ, Moreno J. The pathogenesis of Leishmania/HIV co-infection: cellular and immunological mechanisms. Ann Trop Med Parasitol 2003; 97: S79-98.
90. Tremblay M, Olivier M, Bernier R. Leishmania and the pathogenesis of HIV infection. Parasitol Today 1996; 12: 257-61.
91. Reiner SL, Locksley RM. The regulation of immunity to Leishmania major. Annu Rev Immunol 1995; 13: 151-77.
92. Wolday D, Akuffo H, Britton S, Hathaway A, Sander B. HIV-1 inhibits Leishmania-induced cell proliferation but not production of interleukin-6 and tumour necrosis factor alpha. Scand J Immunol 1994; 39: 380-6.
93. Bhattacharyya S, Ghosh S, Dasgupta B, Mazumder D, Roy S, Majumdar S. Chemokine-induced leishmanicidal activity in murine macrophages via the generation of nitric oxide. J Infect Dis 2002; 185: 1704-8.
94. Haldar JP, Ghose S, Saha KC, Ghose AC. Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis. Infect Immun 1983; 42: 702-7.
95. Gradoni L, Scalone A, Gramiccia M. HIV-Leishmania co-infections in Italy: serological data as an indication of the sequence of acquisition of the two infections. Trans R Soc Trop Med Hyg 1993; 87: 94-6.
96. Medrano FJ, Cañavate C, Leal M, Rey C, Lissen E, Alvar J. The role of serology in the diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type-1. Am J Trop Med Hyg 1998; 59: 155-62.
97. Cacopardo B, Nigro L, Preiser W, Fama A, Satariano MI, Braner J, et al. Prolonged Th2 cell activation and increased viral replication in HIV-Leishmania co-infected patients despite treatment. Trans R Soc Trop Med Hyg 1996; 90: 434-5.
98. Nigro L, Cacopardo B, Preiser W, Braner J, Cinatl J, Palermo F, et al. In vitro production of type 1 and type 2 cytokines by peripheral blood mononuclear cells from subjects coinfected with human immunodeficiency virus and Leishmania infantum. Am J Trop Med Hyg 1999; 60: 142-5.
99. Kalinkovich A, Weisman Z, Bentwich Z. Chemokines and chemokine receptors: role in HIV infection. Immunol Lett 1999; 68: 281-7.
100. Hailu A, Pater JM, Kager PA, Van der Poll T. Increased expression of HIV co-receptor CXCR4 on CD4+ T-cells in patients with active visceral leishmaniasis. Scand J Infect Dis 2004; 36: 56-8.
101. Srebel K, Bour S. Molecular interactions of HIV with human factors. AIDS 1999; 13: S13-24.
102. Fahey JL. Cytokines, plasma immune activation markers, and clinically relevant surrogate markers in human immunodeficiency virus infection. Clin Diagn Lab Immunol 1998; 5: 597-603.
103. Cohen OJ, Fauci AS. Host factors that affect sexual transmission of HIV. Int J Infect Dis 1998; 2: 182-5.
104. Grossman Z, Feinberg MB, Paul WE. Multiple modes of cellular activation and virus transmission in HIV infection: a role for chronically and latently infected cells in sustaining viral replication. Proc Natl Acad Sci USA 1998; 95: 6314-9.
105. Bentwich Z, Kalinkovich A, Weisman Z, Grossman Z. Immune activation in the context of HIV infection. Clin Exp Immunol 1998; 111: 1-2.
106. Anderson RW, Ascher MS, Sheppard HW. Direct HIV cytopathicity cannot account for CD4 decline in AIDS in the presence of homeostasis: a worst-case dynamic analysis. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17: 245-52.
107. Gougeon ML, Montagnier L. Programmed cell death as a mechanism of CD4 and CD8 T cell deletion in AIDS: Molecular control and effect of highly active anti-retroviral therapy. Ann NY Acad Sci 1999; 887: 199-212.
108. Gea-Banacloche JC, Lane HC. Lymphocyte turnover in the setting of HIV infection. Immunologist 1999; 7: 124-31.
109. Hazenberg MD, Stuart JW, Otto SA, Borleffs JC, Boucher CA, De Boer RJ, et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 2000; 95: 249-55.
110. Ribeiro-de-Jesús A, Almeida RP, Lessa H, Bacellar O, Carvalho EM. Cytokine profile and pathology in human leishmaniasis. Braz J Med Biol Res 1998; 31: 143-8.
111. Bernier R, Turco SJ, Olivier M, Tremblay M. Activation of human immunodeficiency virus type 1 in monocytoid cells by the protozoan parasite Leishmania donovani. J Virol 1995; 69: 7282-5.
112. Folks TM, Justement J, Kinter A, Dinarello CA, Fauci AS. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 1987; 238: 800-2.
113. Folks TM, Clouse KA, Justement J, Rabson A, Duh E, Kehrl JH, et al. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci USA 1989; 86: 2365-8.
114. Blackwell JM. Tumour necrosis factor alpha and mucocutaneous leishmaniasis. Parasitol Today 1999; 15 : 73-5.
115. Montalbán C, Martínez-Fernández R, Calleja JL, García-Díaz JD, Rubio R, Dronda F, et al. Visceral leishmaniasis (kala-azar) as an opportunistic infection in patients infected with the human immunodeficiency virus in Spain. Rev Infect Dis 1989; 11 : 655-60.
116. Romeu J, Sirera G, Carreres A, Condom MJ, Clotet B. Visceral leishmaniasis involving the lung and a cutaneous Kaposi's sarcoma lesion. AIDS 1991; 5 :1272.
117. González-Anglada MI, Pena JM, Barbado FJ, González JJ, Redondo C, Galera C, et al. Two cases of laryngeal leishmaniasis in patients infected with HIV. Eur J Clin Microbiol Infect Dis 1994; 13: 509-11.
118. Laguna F. Treatment of leishmaniasis in HIV-positive patients. Ann Trop Med Parasitol 2003; 97 : S135-42.
119. Martínez P, De la Vega E, Laguna F, Soriano V, Puente S, Moreno V, et al. Diagnosis of visceral leishmaniasis in HIV-infected individuals using peripheral blood smears. AIDS 1993; 7 : 227-30.
120. Ramos A, Portero JL, Gazapo T, Yebra M, Portero F, Martín T. Visceral leishmaniasis in immunocompromised patients. An Med Interna 1998; 15 : 301-4.
121. Reus S, Sánchez R, Portilla J, Boix V, Priego M, Merino E, et al. Visceral leishmaniasis: a comparative study of patients with and without human immunodeficiency virus infection. Enferm Infect Microbiol Clin 1999; 17 : 515-20.
122. Evans TG. Leishmaniasis. Infect Dis Clin North Am 1993; 7 : 527-46.
123. Laguna F, López-Vélez R, Pulido F, Salas A, Torre-Cisneros J, Torres E, et al. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. AIDS 1999; 13 : 1063-9.
124. Laguna F, Adrados M, Alvar J, Soriano V, Valencia ME, Moreno V, et al. Visceral leishmaniasis in patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis 1997; 16 : 898-903.
125. Fernández-Guerrero ML, Aguado JM, Buzón L, Barros C, Montalbán C, Martín T, et al. Visceral leishmaniasis in immunocompromised hosts. Am J Med 1987; 83 : 1098-102.
126. Bissuel F, Leport C, Perronne C, Longuet P, Vilde JL. Fever of unknown origin in HIV-infected patients: a critical analysis of a retrospective series of 57 cases. J Intern Med 1994; 236 : 529-35.
127. Miralles P, Moreno S, Pérez-Tascón M, Cosin J, Díaz MD, Bouza E. Fever of uncertain origin in patients infected with the human immunodeficiency virus. Clin Infect Dis 1995; 20 : 872-5.
128. Malebranche R, Arnoux E, Guerin JM, Pierre GD, Laroche AC, Pean-Guichard C, et al. Acquired immunodeficiency syndrome with severe gastrointestinal manifestations in Haiti. Lancet 1983; 2 : 873-8.
129. Janoff EN, Smith PD. Perspectives on gastrointestinal infections in AIDS. Gastroenterol Clin North Am 1988; 17 : 451-63.
130. Muigai R, Gatei DG, Shaunak S, Wozniak A, Bryceson AD. Jejunal function and pathology in visceral leishmaniasis. Lancet 1983; 27 : 476-9.
131. Bryceson ADM. Visceral Leishmaniasis (kala-azar, ponos). In: Wyngardeen JB, Smith LH Jr, editors. Textbook of medicine. 16th ed. Philadelphia: WB Saunders; 1982 p. 1731-4.
132. Serrao-Neto A, Neves-Sousa E, Valente HB, Guimaraes R, Almeida-Ricardo J, Conceicao-Silva FM, et al. An original case of visceral leishmaniasis. Presse Med 1986; 15 : 1286.
133. Betz P, Elsing C, Purrmann J, Frenzel H. Leishmaniasis of the upper gastrointestinal tract in an HIV positive patient. Pathologe 1990; 11 : 97-100.
134. Pesce A, Saint-Paul MC, Vinti H, Marty P, Taillan B, Le Fichoux Y, et al. Gastric leishmaniasis in a patient with acquired immunodeficiency syndrome. Presse Med 1990; 19: 178.
135. Banerjee M, Pal A, Ghosh S, Maitra TK. Small intestinal involvement in visceral leishmaniasis. Am J Gastrenterol 1990; 85 : 1433-4.
136. Sendino A, Barbado FJ, Mostaza JM, Fernández-Martín J, Larrauri J, Vázquez-Rodríguez JJ. Visceral leishmaniasis with malabsorption syndrome in a patient with acquired immunodeficiency syndrome. Am J Med 1990; 87 : 673-5.
137. Villanueva JL, Torre-Cisneros J, Jurado R, Villar A, Montero M, López F, et al. Leishmania esophagitis in an AIDS patient: an unusual form of visceral leishmaniasis. Am J Gastroenterol 1994; 89 : 273-5.
138. McBride MO, Fisher M, Skinner CJ, Golden R, Main J. An unusual gastrointestinal presentation of leishmaniasis. Scand J Infect Dis 1995; 27: 297-8.
139. Mondain-Miton V, Toussaint-Gari M, Hofman P, Marty P, Carles M, De Salvador F, et al. Atypical leishmaniasis in a patient infected with human immunodeficiency virus. Clin Infect Dis 1995; 21 : 663-5.
140. Smith PD, Quinn TC, Strober W, Janoff EN, Masur H. National Institute of Health Conference. Gastrointestinal infections in AIDS. Ann Intern Med 1992; 116 : 63-77.
141. Laguna F, García-Samaniego J, Soriano V, Valencia E, Redondo C, Alonso MJ, et al. Gastrointestinal leishmaniasis in human immunodeficiency virus-infected patients: report of five cases and review. Clin Infect Dis 1994; 19 : 48-53.
142. Perrin C, Taillan B, Hofman P, Mondain V, Lefichoux Y, Michiels JF. Atypical cutaneous histological features of visceral leishmaniasis in acquired immunodeficiency syndrome. Am J Dermatopathol 1995; 17 : 145-50.
143. Dauden E, Penas PF, Rios L, Jiménez M, Fraga J, Alvar J, et al. Leishmaniasis presenting as a dermatomyositis-like eruption in AIDS. J Am Acad Dermatol 1996; 35 : 316-9.
144. Puig L, Pradinaud R. Leishmania and HIV co-infection: dermatological manifestations. Ann Trop Med Parasitol 2003; 97 : S107-14.
145. Calza L, D'Antuono A, Marinacci G, Manfredi R, Colangeli V, Passarini B, et al. Disseminated cutaneous leishmaniasis after visceral disease in a patient with AIDS. J Am Acad Dermatol 2004; 50 : 461-5.
146. Alvar J, Ballesteros JA, Soler R, Benito A, van Eys GJ, Schoone GJ, et al. Mucocutaneous leishmaniasis due to Leishmania (Leishmania) infantum: biochemical characterzation. Am J Trop Med Hyg 1990; 43 : 614-8.
147. Miralles ES, Nuñez M, Hilara Y, Harto A, Moreno R, Ledo A. Mucocutaneous leishmaniasis and HIV. Dermatology 1994; 189 : 275-7.
148. Duarte MIS, Matta VLR, Corbett CEP, Laurenti MD, Chebabo R, Goto H. Interstitial pneumonitis in human visceral leishmaniasis. Trans R Soc Trop Med Hyg 1989; 83 : 73-6.
149. Dutra M, Martinelli R, De Carvalho M, Rodrigues L, Brito E, Rocha H. Renal involvement in visceral leishmaniasis. Am J Kidney Dis 1985; 6 : 22-7.
150. Van Velthuysen ML, Florquin S. Glomerulopathy associated with parasitic infections. Clin Microbiol Rev 2000; 13 : 55-6.
151. Clevenbergh P, Okome MN, Benoit S, Bendini JC, De Salvador F, Elbeze M, et al. Acute renal failure as initial presentation of visceral leishmaniasis in an HIV-1-infected patient. Scand J Infect Dis 2002; 34 : 546-7.
152. López-Vélez R, Laguna F, Alvar J, Pérez-Molina JA, Molina R, Martínez P, et al. Parasitic culture of buffy coat for diagnosis of visceral leishmaniasis in human immunodeficiency virus-infected patients. J Clin Microbiol 1995; 33 : 937-9.
153. Nigro L, Montineri A, La Rosa R, Zuccarello M, Iacobello C, Iacobello C, et al. Visceral leishmaniasis and HIV co-infection: a rare case of pulmonary and oral localization. Infez Med 2003; 11 : 93-6.
154. Greder A, Malet M, Gautier P, Lassaigne D, Duhamel C, Lamy C, et al. Pleurisy revealing leishmaniasis in acquired immunodeficiency syndrome. Presse Med 1989; 18 : 1390-1.
155. Laguna F, García-Samaniego J, Moreno V, González-Lahoz JM. Prevalence of gastrointestinal leishmaniasis in Spanish HIV-positive patients with digestive symptoms. Am J Gastroenterol 1994; 89 : 1606.
156. Olofinlade O, Cacciarelli, A. Treatment of the wrong disease with the right medication: a case of generalized leishmaniasis involving the liver and the gastrointestinal tract. Am J Gastroenterol 2000; 95 : 1377.
157. Ramos CC, Duarte MI, Ramos AM. Fatal visceral leishmaniasis associated with acquired immunodeficiency syndrome: report of a case with necropsy findings and immunohistochemical study. Rev Soc Bras Med Trop 1994; 27: 245-50.
158. Vázquez-Piñeiro T, Fernández-Álvarez JM, Gonzalo-Lafuente JC, Cano J, Gimeno M, Berenguer J. Visceral leishmaniasis: a lingual presentation in a patient with HIV infection. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 86 : 179-82.
159. Rosenthal E, Marty P, Del Giudice P, Pradier C, Ceppi C, Gastaut JA, et al. HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania. Clin Infect Dis 2000; 31: 1093-5.
160. Mofredj A, Guerin JM, Leibinger F, Masmoudi R, Visceral leishmaniasis with pericarditis in an HIV-infected patient. Scand J Infect Dis 2002; 34: 151-3.
161. Rosenthal E, Marty P, Le Fichoux Y, Cassuto JP. Clinical manifestations of visceral leishmaniasis associated with HIV infection: a retrospective study of 91 French cases. Ann Trop Med Parasitol 2000; 94: 37-42.
162. Navarro CM. Isolateral laryngeal Leishmania in an immunocompetent patient: successful treatement with surgery. J Laryngol Otol 1994; 108: 249-51.
163. Bryceson ADM. Leishmaniasis. In: Cook GC, editor. Manson's tropical diseases. 20th ed. London: WB Saunders Company Ltd.; 1996 p. 1213-45.
164. Hamour AA, Skelly R, Jowitt SN, Wilson GE, Curry A, Wilkins EG, et al. Visceral leishmaniasis (Kala-azar) in two patients with HIV-1 infection: atypical features and response to therapy. J Infect 1998; 36: 217-20.
165. Lachaud L, Dereure J, Chabbert E, Reynes J, Mauboussin JM, Oziol E, et al. Optimized PCR using patient blood samples for diagnosis and follow-up of visceral leishmaniasis, with special reference to AIDS patients. J Clin Microbiol 2000; 38: 236-40.
166. Altés J, Salas A, Riera M, Udina M, Galmes A, Balanzat J, et al. Visceral leishmaniasis: another HIV-associated opportunistic infection? Report of eight cases and review of the literature. AIDS 1991; 5: 201-7.
167. Dereure J, Reynes J, Pratlong F, Lamaury I, Rioux JA, Janbon F, et al. Visceral leishmaniasis in HIV-infected patients in the south of France. Bull World Health Organ 1995; 73: 245-6.
168. Piarroux R, Gambarelli F, Dumon H, Fontes M, Dunan S, Mary C, et al. Comparison of PCR with direct examination of bone marrow aspiration, myeloculture, and serology for diagnosis of visceral leishmaniasis in immunocompromised patients. J Clin Microbiol 1994; 32: 746-9.
169. Medrano F J, Jiménez-Mejías E, Calderón E, Regordán, C, Leal M. An easy and quick method for the diagnosis of visceral leishmaniasis in HIV-1-infected individuals. AIDS 1993; 7: 1399.
170. Delgado J, Pineda JA, Macías J, Regordan C, Gallardo JA, Leal M, et al. Low sensitivity of peripheral blood smear for diagnosis of subclinical visceral leishmaniasis in human immunodeficiency virus type 1-infected patients. J Clin Microbiol 1998; 36: 315-6.
171. Mathis A, Deplazes P. PCR and in vitro cultivation for detection of Leishmania spp. in diagnostic samples from humans and dogs. J Clin Mic 1995; 33: 1145-9.
172. Pintado V, López-Vélez R. HIV-associated visceral leishmaniasis. Clin Microbiol Infect 2001; 7: 291-300.
173. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med 1983; 309: 453-8.
174. Williams RO. Invasion of murine dendritic cells by Leishmania major and L. mexicana mexicana. J Parasitol 1988; 74: 186-7.
175. Mary C, Lamouroux D, Dunan S, Quilici M. Western blot analysis of antibodies to Leishmania infantum antigens: potential of the 14-kD and 16-kD antigens for diagnosis' and epidemiologic purposes. Am J Trop Med Hyg 1992; 47: 764-71.
176. Gari-Toussaint M, Lelievre A, Marty P, Le Fichoux Y. Contribution of serological tests to the diagnosis of visceral leishmaniasis in patients infected with the human immunodeficiency virus. Trans R Soc Trop Med Hyg 1994; 88: 301-2.
177. Hviid L, Sorensen AL, Kharazmi A, Theander TG. Functional and phenotypic changes in human lymphocytes after coincubation with Leishmania donovani in vitro. Infect Immun 1990; 58: 3163-7.
178. Ho M, Koech DK, Iha DW, Bryceson AD. Immunosuppression in Kenyan visceral leishmaniasis. Clin Exp Immunol 1983; 51: 207-14.
179. Sacks DL, Lal SL, Shrivastava SN, Blackwell J, Neva FA. An analysis of T cell responsiveness in Indian kala-azar. J Immunol 1987; 138: 908-13.
180. Carvalho EM, Teixeira RS, Johnson WD Jr. Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection. Infect Immun 1981; 33: 498-500.
181. Ghose AC, Haldar JP, Pal SC, Mishra BP, Mishra KK. Serological investigations on Indian kala-azar. Clin Exp Immunol 1980; 40: 318-26.
182. Murray HW, Oca MJ, Granger AM, Schreiber RD. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. J Clin Invest 1989; 83: 1253-7.
183. Leeuwenburg J, Bryceson AD, Mbugua GG, Siongok TK. The use of the leishmanin skin-test to define transmission of leishmaniasis in Baringo district, Kenya. East Afr Med J 1983; 60: 81-4.
184. Kurtzhals JA, Hey AS, Theander TG, Odera E, Christensen CB, Githure JI, et al. Cellular and humoral immune responses in a population from the Baringo District, Kenya to Leishmania promastigote lipophosphoglycan. Am J Trop Med Hyg 1992; 46: 480-8.
185. Coutinho SG, Da-Cruz AM, de Oliveira MP, Mendonca SC, Bertho AL, De Luca P. CD4+ and CD8+ T cell immune responses of immunocompetent and immunocompromised (AIDS) patients with American tegumentary leishmaniasis. Mem Inst Oswaldo Cruz 1996; 91: 381-4.
186. Moreno J, Cañavate C, Chamizo C, Laguna F, Alvar J. HIV-Leishmania infantum co-infection: humoral and cellular immune responses to the parasite after chemotherapy. Trans R Soc Trop Med Hyg 2000; 94: 328-32.
187. Badaró R, Benson D, Eulalio MC, Freire M, Cunha S, Netto EM, et al. rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. J Infect Dis 1996; 173: 758-61.
188. Deniau M, Cañavate C, Faraut-Gambarelli F, Marty P. The biological diagnosis of leishmaniasis in HIV-infected patients. Ann Trop Med Parasitol 2003; 97: S115-33.
189. Hailu A, Berhe N. The performance of direct agglutination tests (DAT) in the diagnosis of visceral leishmaniasis in Ethiopian patients with HIV co-infection. Ann Trop Med Parasitol 2002; 96: 25-30.
190. Vilaplana C, Blanco S, Domínguez J, Giménez M, Ausina, V, Tural C, et al. Noninvasive method for diagnosis of visceral leishmaniasis by a latex agglutination test for detection of antigens in urine samples. J Clin Microbiol 2004; 42: 1853-4.
191. Campino L, Cortes S, Pires R, Oskam L, Abranches P. Detection of Leishmania in immunocompromised patients using peripheral blood spots on filter paper and the polymerase chain reaction. Eur J Clin Microbiol Infect Dis 2000; 19: 396-8.
192. Pizzuto M, Piazza M, Senese D, Scalamogna C, Calattini S, Corsico L, et al. Role of PCR in diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type 1. J Clin Microbiol 2001; 39: 357-61.
193. Bretagne S, Durand R, Olivi M, Garin JF, Sulahian A, Rivollet D, et al. Real-time PCR as a new tool for quantifying Leishmania infantum in liver in infected mice. Clin Diagn Lab Immunol 2001; 8: 828-31.
194. Nicolas L, Prina E, Lang T, Milon G. Real-time PCR for detection and quantitation of Leishmania in mouse tissues. J Clin Microbiol 2002; 40: 1666-9.
195. Schulz A, Mellenthin K, Schonian G, Fleischer B, Drosten C. Detection, differentiation, and quantitation of pathogenic Leishmania organisms by a fluorescence resonance energy transfer-based real-time PCR assay. J Clin Microbiol 2003; 41: 1529-35.
196. Bossolasco S, Gaiera G, Olchini D, Gulletta M, Martello L, Bestetti A, et al. Real-time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis. J Clin Microbiol 2003; 41: 5080-4.
197. Mary C, Faraut F, Lascombe L, Dumon H. Quantification of Leishmania infantum DNA by Real-time PCR assay with high sensitivity. J Clin Microbiol 2004; 42: 5249-55.
198. Liew F, Millot S, Parkinson C, Palmer R, Moncada S. Macrophage killing of Leishmania parasites in vivo is mediated by nitric oxid from L-arginine. J Immunol 1990; 144: 4794-7.
199. Barral-Neto M, Badaró B, Barral A. Tumor necrosis factor (cachectin) in human visceral leishmaniasis. J Infect Dis 1991; 163: 853-7.
200. Bacellar O, Barral-Neto M, Badaró R, Carvalho E. Gamma interferon production by lymphocytes from children infected with L. chagasi. Braz J Med Biol Res 1991; 24: 791-5.
201. Carvalho E, Barral A, Pedral-Sampaio D. Immunological markers of clinical evolution in children recently infected with Leishmania dnovani chagasi. J Infect Dis 1992; 165: 535-40.
202. Carvalho EM, Correia Filho D, Bacellar O, Almeida RP, Lessa H, Rocha H. Characterization of the immune response in subjects with self-healing cutaneous leishmaniasis. Am J Trop Med Hyg 1995; 53 : 273-7.
203. Ghalib H, Wittle J, Kubin M. IL-12 enhances Th1-type responses in human Leishmania donovani infections. J Immunol 1995; 154 : 4623-9.
204. Sang D, Ouma J, John CC, Wholen CC, King CL, Mahmond AA, et al. Increased levels of soluble interleukin-4 receptor in the sera of patients with visceral leishmaniasis. J Infect Dis 1999; 179: 743-6.
205. Awasthi A, Mathur RK, Saha B. Immune response to Leishmania infection. Indian J Med Res 2004; 119 : 238-58.
206. Gama MEA, Costa JML, Pereira JCR, Gomes CMC, Corbett CEP. Serum cytokine profile in the subclinical form of visceral leishmaniasis. Braz J Med Biol Res 2004; 37: 129-36.
207. Goto H, Lindoso JAL. Immunity and immunosupression in experimental visceral leishmaniasis. Braz J Med Biol Res 2004; 37: 615-23.
208. Holaday B, Pompeu M, Evans T, Braga DN, Texeira MJ, Sousa A de Q, et al. Correlates of Leishmania-specific immunity in the clinical spectrum of infection with Leishmania chagasi. J Infect Dis 1993; 167: 411-7.
209. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on denditric cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996; 184 : 742-52.
210. Stober D, Schirmbeck R, Reimann J. IL-12/1L-18-dependent IFN-gamma release by murine dendritic cells. J Immunol 2001; 167: 957-65.
211. Qi H, Denning TL, Soong L. Differential induction of interleukin-10 and interleukin-12 in denditric cells by microbial toll-like receptor activators and skewing of T-cell cytokine profiles. Infect Immun 2003; 71 : 3337-42.
212. Leishman W. Handbuch der Tropenkrankheiten. 2nd ed. Leipzig, Germany.
213. Guerra M, Furtado T, Barros G, Sessa P, Daher V. InfecÇâo sublínica na leishmaniose tegumentar. An Bras Dermatol 1985; 60 : 365-9.
214. D'Oliveira A Jr, Costa S, Barbosa A, Orge M, Carvalho E. Asymptomatic Leishmania chagasi infection in relatives and neighbors of patients with visceral leishmaniasis. Mem Inst Oswaldo Cruz 1997; 92 : 15-20.
215. Gama M. Perfil clínico e laboratorial da forma oligossintomática da leishmaniose visceral americana. Tesis Doctoral, Departamento de Patologia, Faculdade de Medicina, Universidade de Sâo Paulo, SP, Brasil 2001.
216. Croft SL, Coombs GH. Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 2003; 19 : 502-8.
217. Williams JE. Leishmania and Trypanosoma. In: Gillespie SH, Hawkey PM, editors. Medical parasitology. A practical approach. New York, USA: Oxford University Press; 1995.
218. Karplus TM, Jeronimo SMB, Chang H, Helms BK, Burns TL, Murray JC, et al. Association between the tumor necrosis factor locus and the clinical outcome of Leishmania chagasi infection. Infect Immun 2002; 70 : 6919-25.
219. Beutler BA. The role of tumor necrosis factor in health and disease. J Rheumatol 1999; 26 : S16-21.
220. Parham P. Chapter 8: The Body's defenses against infection. In: The immune system. New York, USA: Garland Publishing, Taylor & Francis Group; 2000 p. 214-6.
221. Grau GE, Kossodo S, Mazier D, Milon G. Chapter 7: Cytokines and parasitic diseases. In: Oppenheim JJ, Rossio JL, Gearing AJH, editors. Clinical applications of citokines. Role in pathogenesis, diagnosis and therapy. New York, USA: Oxford University Press; 1993 p. 49-59.
222. Oppenheim J, Ruscetti F, Faltynek C. Citocinas. In: Stiles D, Abba T. editors. Imunologia Básica. Brazil: Revinter, Rio de Janeiro, RJ; 1991 p. 61-76.
223. Stevens D. Cytokines: an updated compendium. Curr Opin Infect Dis 1995; 8: 175-80.
224. Janeway C, Travers P. Imunologia: O Sistema Imunológico na Saúde e na DoenÇa. RS, Brazil: Artes Médicas, Porto Alegre; 1997.
225. Mellors JW, Griffith BP, Ortiz MA, Landry ML, Ryan JL. Tumor necrosis factor alpha/cachectin enhances human human immunodeficiency virus type 1 replication in primary macrophages. J Infect Dis 1991; 163 : 78-82.
226. Aukrust P, Liabakk NB, Muller F, Lien E, Espevik T, Froland SS. Serum levels of tumor necrosis factor-alpha (TNF-α) and soluble TNF receptors in human immunodeficiency virus type 1 infection-correlations to clinical, immunologic and virologic parameters. J Infect Dis 1994; 169 : 420-4.
227. Cenini P, Berhe N, Hailu A, McGinnes K, Frommel D. Mononuclear cell subpopulations and cytokine levels in human visceral leishmaniasis before and after chemotherapy. J Infect Dis 1993; 168 : 986-93.
228. Laguna F, López-Vélez R, Soriano V, Montilla P, Alvar J, González-Lahoz JM. Assessment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients with HIV. J Infect 1994; 28: 255-9.
229. Santos J, Rivero A, Marquez M. Acute pancreatitis with a fatal evolution due to antimonials in patients with visceral leishmaniasis and HIV infection. Ann Med Interna 2000; 7: 562-3.
230. Delgado J, Macías J, Pineda JA, Corzo JA, González-Moreno MP, de la Rosa R, et al. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. Am J Trop Med Hyg 1999; 61 : 766-9.
231. Maddux MS, Barriere SL, A review of complications of cmphotericin-B teraphy: Recomendations for prevention and management. Drug Intell Clin Pharm 1980; 14 : 177-95.
232. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12 : 308-23.
233. Moreau P, Milpied N, Fayette N, Ramée JF, Harousseau JL. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. J Antimicrob Chemother 1992; 30: 535-41.
234. Butler WT, Bennett JE, Alling DW, Wertlake PI, Otz Jr, Hill GJ III. Nephrotoxicity of amphotericin B: early and late effects in 81 patients. Ann Intern Med 1964; 61 : 175-87.
235. Hiemenz JW, Walsh TJ. Lipid formulations of amphptericin B: Recent progress and future directions. Clin Infect Dis 1996; 22 : 133-44.
236. Hoeprich PD. Clinical use of amphotericin B and derivatives: Lore, mystique, and Fact. Clin Infect Dis 1992; 14 : 114-9.
237. Hoeprich PD. Elimination half-life of amphotericin B. Br J Infect 1990; 20: 173-5.
238. Thakur CP. Comparison of glucose versus fat emulsion in the preperation of anphotericine B for use in kala-azar. Trans R Soc Trop Med Hyg 1994; 88: 698-9.
239. Mishra M, Biswas UK, Jha DN, Khan AB. Amphotericin versus pentamidine in antimony-unresponsive kala-azar. Lancet 1992; 340 : 1256-7.
240. Mishra M, Biswas UK, Jha DN, Khan AB. Amphotericin versus sodium stibogluconate in first-line treatment of indian kala-azar. Lancet 1994; 344 : 1599-600.
241. Thakur CP, Sinha GP, Sharma V, Barat D. The treatment of kala-azar during pregnancy. Natl Med J India 1993; 6 : 263-5.
242. Fielding RM. Liposomal drug delivery. Clin Pharmacokinet 1991; 21 : 155-64.
243. Davidson RN, Dimartino L, Gradoni L, Giacchino R, Russo R, Gaeta GB, et al. Liposomal amphotericin B (AmBisome) in mediterranean visceral leishmaniasis: a multi-centre trial. Quaterly J Med 1994; 87 : 75-81.
244. Davidson RN, Di Martino L, Gradoni L, Giacchino R, Gaeta GB, Pempinello R, et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 1996; 22 : 938-43.
245. Seaman J, Boer C, Wilkinson R, Jong J, Wilde E, Sondorp E, et al. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin Infect Dis 1995; 21 : 188-93.
246. Thakur CP, Pandey AK, Sinha GP, Roy S, Behbehani K, Olliaro P. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome®) for visceral leishmaniasis in India: a randomized dose-finding study. Trans R Soc Trop Med Hyg 1996; 90: 319-22.
247. Dietze R, Milan EP, Berman JD, Grogl M, Falqueto A, Feitosa TF, et al. Treatment of brazilian kala-azar with a short course of Amphocil (Amphotericin B Cholesterol Dispersion). Clin Infect Dis 1993; 17: 981-6.
248. Sundar S, Murray HW. Cure of antimony-unresponsive indian visceral leishmaniasis with amphotericin B lipid complex. J Infect Dis 1996; 173 : 762-5.
249. Sundar S, Agrawal NK, Sinha PR, Horwith GS, Murray HW. Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med 1997; 127: 133-7.
250. Herbrecht R, Sosa C, Himy R, Villard O. Successful treatment of visceral leishmaniasis with high-dose amohotericin B diluted in fat emulsion: a case report. Trans R Soc Trop Med Hyg 1996; 90:322-3.
251. Russo R, Nigro LC, Minniti S, Montineri A, Gradoni L, Cladeira L, et al. Visceral leishmaniasis in HIV infected patients with high dose liposomal amphotericin B (AmBisome). J Infect 1996; 32 : 133-7.
252. Torre-Cisneros J, Villanueva JL, Kindellan JM, Jurado R, Sánchez-Guijo P. Succesful treatment of antimony resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus. Clin Infect Dis 1993; 17: 625-7.
253. Boletis JN, Pefanis A, Stathakis C, Helioti H, Kostakis A, Giamarellou H. Visceral leishmaniasis in renal transplant recipients: succesful treatment with liposomal amphotericin B (Ambisome). Clin Infect Dis 1999; 28: 1308-9.
254. Berman JD, Dawver DM, Wyler DJ. Multiplication of Leishmania in human macrophages in vitro. Infect Immun 1979; 26: 275-9.
255. Jha SN, Singh NK, Jha TK. Changing response to diamidine compounds in cases of kala-azar unresponsives to antimonials. J Assoc Physicians India 1991; 39: 314-6.
256. Hentzer B, Kobayasi T. The ultrastructural changes of Leishmania tropica after treatment with pentamidine. Ann Trop Med Parasitol 1977; 71 : 157-66.
257. Murray HW, Hariprashad J, Fichtl RE. Treatment of experimental visceral leishmaniasis in a T-cell-deficient host response to amphotericin B and pentamidine. Antimicrob Agents Chemother 1993; 37: 1504-5.
258. Thakur CP, Kumar M, Pandey AK. Comparison of regimes of treatment of antimony-resistant kala-azar patients: a randomized study. Am J Trop Med Hyg 1991; 45: 435-41.
259. Soto-Mancipe J, Grogl M, Berman JD. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin Infect Dis 1993; 16: 417-25.
260. Neal RA. The effect of antibiotics of the neomycin group on experimental cutaneous leishmaniasis. Ann Trop Med Parasitol 1968; 62 : 54-62.
261. Maarouf M, Adeline MT, Solignac M, Vautrin D, Robert-Gero M. Development and characterization of paromomycin-resistant Leishmania donovani promastigotes. Parasite 1998; 5 : 167-73.
262. Thakur CP, Bhowmick S, Dolfi L, Olliaro P. Aminosidine plus sodium sitobgluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial. Trans R Soc Trop Med Hyg 1995; 89: 219-3.
263. Chunge CN, Owate J, Pamba HO, Donno L. Treatment of visceral leishmaniasis in Kenia by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg 1990; 84: 221-5.
264. Thakur CP, Olliaro P, Gothoskar S, Bhowmick S, Choudhury BK, Prasad S, et al. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (=paramomicine)-antimonial combination, a pilot study in Bihar, India. Trans R Soc Trop Med Hyg 1992; 86: 615-6.
265. Seaman J, Pryce D, Sondorp HE, Moody A, Brycesson AD, Davidson RN. Epidemic visceral leishmaniasis in Sudan: A randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J Infect Dis 1993; 168: 715-20.
266. Berman JD. Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997 10-15 April, 2005; 24 : 684-703.
267. Jha TK, Sundar S, Bhattacharya SK, Sinha PK, Thakur CP. Paramomicyn as a new cure for visceral leishmaniasis: preliminary results of a phase III randomised controlled trial of efficacy and safety. Third World Congress on Leishmaniasis, Palermo-Terrasini, Sicily (Italy) 10-15 April, 2005; 2205.33.
268. Urbina JA. Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites. Parasitology 1997; 114 : S91-9.
269. Murray HW, Delph-Etienne S. Visceral leishmanicidal activity of hexadecylphosphocoline (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms. J Infect Dis 2000; 181 : 795-9.
270. Murray HW, Delph-Etienne S. Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect Immun 2000; 68 : 288-93.
271. Murray HW. Suppression of posttreatment recurrence of experimental visceral leishmaniasis in T-cell-deficient mice by oral miltefosine. Antimicrob Agents Chemother 2000; 44 : 3235-6.
272. Kuhlencord A, Maniera T, Eibl H, Unger C. Hexadecylphophocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother 1992; 36: 1630-4.
273. Le Fichoux Y, Rousseau D, Ferrua B, Ruette S, Lelievre A, Grousson D, et al. Short- and long-term efficacy of hexadecylphophocholine against established Leishmania infantum infection in BALB/c mice. Antimicrob Agents Chemother 1998; 42 : 654-8.
274. Schmidt-Ott R, Klenner T, Overath P, Aebischer T. Topical treatment with hexadecylphophocholine (Miltex®) effiently reduces parasite burden in experimental cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1999; 93 : 85-90.
275. Sundar S, Rosenkaimer F, Makharia MK, Goyal AK, Mandal AK, Voss A, et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet 1998; 352 : 1821-3.
276. Sundar S, Gupta LB, Makharia MK, Singh MK, Voss A, Rosenkaimer F, et al. Oral treatment of visceral leishmaniasis with miltefosine. Ann Trop Med Parasitol 1999; 93 : 589-97.
277. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis,. N Engl J Med 1999; 341 : 1795-800.
278. Sundar S, Makharia A, More DK, Agrawal G, Voss A, Fisher C, et al. Short-course of oral miltefosine treatment of visceral leishmaniasis. Clin Infect Dis 2000; 31 : 1110-3.
279. Sindermann H, Engel KR, Fischer C, Bommer W, Miltefosine Compassionate Use Program. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin Infect Dis 2004; 39: 1520-3.
280. Choi CM, Lerner EA. Leishmaniasis: recognition and management with a focus on the immunocompromised patient. Am J Clin Dermatol 2002; 3 : 91-105.
281. Kager PA, Rees PH, Wellde BT, Hockmeyer WT, Lyerly WH. Allopurinol in the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 1981; 75 556-9.
282. Jha TK. Evaluation of allopurinol in the treatment of kala-azar occurring in North Bihar, India. Trans R Soc Trop Med Hyg 1983; 77: 204-7.
283. Halim MA, Alfurayh O, Kalin ME, Dammas S, al-Eisa A, Damanhouri G. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in a renal transplant recipient after the occurrence of pancreatitis due to stibogluconate. Clin Infect Dis 1993; 16 :397-9.
284. Baum KF, Berens RL. Successful treatment of cutaneous leishmaniasis with allopurinol after failure of treatment with ketoconazole. Clin Infect Dis 1994; 18 : 813-5.
285. Chunge CN, Gachihi G, Muigai R, Wassuna A, Rachid JR, Chulay JD, et al. Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment useing a combination of sodium stibogluconate plus allopurinol. Trans R Soc Trop Med Hyg 198.5; 79: 715-8.
286. Di Martino L, Mantovani MP, Gradoni L, Gramiccia M, Guandalini S. Low dosage combination of meglumine antimoniate plus allopurinol as first choice treatment of infantile visceral leishmaniasis in Italy. Tans R Soc Trop Med Hyg 1990; 84 : 534-5.
287. Gachihi GS, Were JBO, Coyne PE, Muigai RK, Nyakundi PM, Wasunna KMA, et al. A prospective randomized trial of sodium stibogluconate alone versus sodium stibogluconate plus allopurinol in the treatment of visceral leishmaniasis in Kenya. Proceedings XIIIth Int Congress Trop Med Malaria. Jomlien. Pattaya. Thailand. 1992; Abstract no. TuP8-13.
288. Ribera E, Ocaña I, de Otero J, Cortes I, Gasser I, Pahissa A. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. Am J Med 1996; 100 : 496-501.
289. Badaró R, Falcoff E, Badaro FS, Carvalho EM, Pedral-Sampaio D, Barral A, et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon-γ. N Eng J Med 1990; 322: 16-21.
290. Squires KE, Rosenkaimer F, Sherwood JA, Forni AL, Were JB, Murray HW. Immunochemotherapy for visceral leishmaniasis: a controlled pilot trial of antimony versus antimony plus interferon-gamma. Am J Trop Med Hyg 1993; 48 : 666-9.
291. Sundar S, Rosenkaimer F, Lesser ML, Murray HW. Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis. J Infect Dis 1995; 171 : 992-6.
292. Sundar S, Murray HW. Effect of treatment with interferon-gamma alone in visceral leishmaniasis. J Infect Dis 1995; 172: 1627-9.
293. Smith AC, Yardley V, Rhodes J, Croft SL. Activity of the novel immunomodulatory compound tucaresol against experimental visceral leishmaniasis. Antimicrob Agents Chemother 2000; 44 : 1494-8.
294. Badaró R, Nascimento C, Carvalho JS, Badaro F, Russo D, Ho JL, et al. Recombinant human granulocyte-macrophage colony-stimulating factor reverses neutropenia and reduces secondary infections in visceral leishmaniasis. J Infect Dis 1994; 170: 413-8.
295. Scharton-Kersten T, Afonso LC, Wysocka M, Trinchieri G, Scott P. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J Immunol 1995; 154 : 5320-30.
296. Nabors GS, Afonso LC, Farrell JP, Scott P. Switch from a type 2 to a type I T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with IL- 12 and Pentostam. Proc Natl Acad Sci USA 1995; 92 : 3142-6.
297. Soriano V, Dona C, Rodríguez-Rosado R, Barreiro P, González-Lahoz J. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2000; 14: 383-6.
298. Berenguer J, Cosin J, Miralles P, López JC, Padilla B. Discontinuation of secondary prophylaxis in HIV-infected patients who have responded to highly active anti retroviral therapy. AIDS 2000; 14 : 2946-58.
299. WHO. Leishmania/HIV co-infection, South-western Europe 1990-1998. Geneva: World Health Organization; mimeographed document 2000 WHO/LEISH/ 2000.42 2000.
300. Rosenthal E, Marty P. Recent understanding in the treatment of visceral leishmaniasis. J Postgrad Med 2003; 49 : 61-8.
301. López-Vélez R, Videla S, Márquez M, Boix V, Jiménez-Mejías ME, Górgolas M, et al. Spanish HIV-Leishmania Study Group. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 2004; 53 : 540-3.
302. Montana M, Chochoi N, Monges P, Ravaux I, Faraut F, Gensollen S, et al. Liposomal amphotericin B in secondary prophylaxis of visceral leishmaniasis in HIV-infected patients: report of five clinical cases. Pathol Biol (Paris) 2004; 52 : 66-75.
303. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999; 341 : 255-9.